ivabradine Side Effects
Also known as: Corlanor
Analysis of 6,539 adverse event reports submitted to the FDA from 2007 to 2025.
Total Reports
6,539
Death-Related
494
7.6% of reports
Hospitalizations
2,361
36.1% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 494 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 142 |
| CARDIAC FAILURE | 63 |
| HYPOTENSION | 42 |
| PNEUMONIA | 37 |
| DYSPNOEA | 34 |
| ACUTE KIDNEY INJURY | 28 |
| CARDIAC ARREST | 28 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 22 |
| PYREXIA | 21 |
| FALL | 19 |
| ARRHYTHMIA | 18 |
| SEPSIS | 18 |
| TOXICITY TO VARIOUS AGENTS | 18 |
| EJECTION FRACTION DECREASED | 17 |
| INTENTIONAL OVERDOSE | 17 |
| BEZOAR | 16 |
| DRUG INEFFECTIVE | 16 |
| FEBRILE NEUTROPENIA | 16 |
| PNEUMONIA ASPIRATION | 16 |
| CONDITION AGGRAVATED | 15 |
Reactions in Hospitalization Reports
Top reactions in 2,361 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| HYPOTENSION | 257 |
| DYSPNOEA | 256 |
| CARDIAC FAILURE | 246 |
| DRUG INTERACTION | 167 |
| OFF LABEL USE | 142 |
| BRADYCARDIA | 132 |
| DIZZINESS | 131 |
| DRUG INEFFECTIVE | 130 |
| ACUTE KIDNEY INJURY | 123 |
| FATIGUE | 117 |
| OEDEMA PERIPHERAL | 112 |
| NAUSEA | 96 |
| CHEST PAIN | 91 |
| PNEUMONIA | 90 |
| HEADACHE | 89 |
| SYNCOPE | 89 |
| ASTHENIA | 85 |
| PULMONARY OEDEMA | 85 |
| FALL | 84 |
| MALAISE | 82 |
Nearby — Related Medications
What the FAERS Data Reveals About ivabradine Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 6,539 voluntary reports linked to ivabradine and its brand equivalents (Corlanor), spanning 2007 through 2025. Of those, 494 (7.6%) listed death as an outcome and 2,361 (36.1%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 58% were female and 42% male; age distribution skews toward 45-64, with 1,578 reports in that bracket. The single most reported reaction is off label use with 1,295 submissions, followed by dyspnoea and hypotension.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.